MS4A1 and myeloid sarcoma: However, it is now known that B cells are key contributors to MS immunopathology, as demonstrated by the observed clinical efficacy of CD20‐targeting, B‐cell‐depleting therapies in relapsing MS.15, 16, 17, 18, 19, 20, 21, 22, 23